April 22, 2009--Nippon Boehringer Ingelheim Co., Ltd. and Astellas Pharma Inc. announced today that on 22 April the approval of manufacture and marketing of Micombi Combination Tablets was obtained. Micombi is a combination drug of telmisartan, an angiotensin II receptor blocker, and hydrochlorothiazide, a diuretic of the thiazide class.
The details can be read here.
No comments:
Post a Comment